Cargando…
PD-1抑制剂治疗复发或难治性经典型霍奇金淋巴瘤的疗效和安全性分析
OBJECTIVE: This retrospective, single-center study aimed to evaluate the efficacy and safety of programmed death-1(PD-1)inhibitors, either as monotherapy or in combination with chemotherapy, in the management of relapse/refractory classical Hodgkin's lymphoma(R/R cHL). METHODS: A total of 35 pa...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509629/ https://www.ncbi.nlm.nih.gov/pubmed/37749034 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.07.005 |
Ejemplares similares
-
单倍型造血干细胞移植治疗26例复发难治侵袭性非霍奇金淋巴瘤疗效和安全性研究
Publicado: (2016) -
IGEV方案治疗复发难治性霍奇金淋巴瘤的临床研究
Publicado: (2018) -
新免疫治疗时代下复发难治性霍奇金淋巴瘤治疗新策略
Publicado: (2019) -
卡瑞利珠单抗联合AVD方案一线治疗经典型霍奇金淋巴瘤的有效性和安全性
Publicado: (2022) -
Brentuximab vedotin联合氮芥治疗六例复发难治性霍奇金淋巴瘤疗效分析
Publicado: (2015)